1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,950 | 7,100 | 11:49 | |
| 6,950 | 7,150 | 06.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.01. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 1 | GlobeNewswire (USA) | ||
| 19.11.25 | Elicio Therapeutics appoints Marc Wolfgang as chief technology officer | 1 | Investing.com | ||
| ELICIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 19.11.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer | 395 | GlobeNewswire (Europe) | BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies... ► Artikel lesen | |
| 13.11.25 | Elicio Therapeutics GAAP EPS of -$0.60 misses by $0.12 | 2 | Seeking Alpha | ||
| 13.11.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates | 180 | GlobeNewswire (Europe) | In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma ("PDAC"), fewer disease progressions and deaths than projected have been observed as... ► Artikel lesen | |
| 07.11.25 | Elicio meldet starke Immunantworten in Phase-2-Studie zu KRAS-Krebsimpfstoff | 1 | Investing.com Deutsch | ||
| 07.11.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC | 218 | GlobeNewswire (Europe) | SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapyELI-002... ► Artikel lesen | |
| 27.10.25 | Krebstherapie von Elicio zeigt breite Immunantwort bei diversen HLA-Typen | 1 | Investing.com Deutsch | ||
| 27.10.25 | Elicio's cancer therapy shows immune response across diverse HLA types | 1 | Investing.com | ||
| 18.09.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 212 | GlobeNewswire (Europe) | BOSTON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies... ► Artikel lesen | |
| 17.09.25 | Elicio Reports Strong T Cell Responses In Phase 2 Trial Of Cancer Vaccine | 1 | RTTNews | ||
| 17.09.25 | Elicio: Krebsimpfstoff ELI-002 löst bei 99 % der Patienten starke Immunantwort aus | 2 | Investing.com Deutsch | ||
| 17.09.25 | Elicio's cancer vaccine ELI-002 shows strong immune response in 99% of patients | 2 | Investing.com | ||
| 17.09.25 | Elicio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.09.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial | 212 | GlobeNewswire (Europe) | ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational vaccine immunotherapyRobust mKRAS-specific T cell responses were observed... ► Artikel lesen | |
| 12.08.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease ("MRD") Positive, Adjuvant-Stage Patients | 221 | GlobeNewswire (Europe) | At extended median follow-up of 19.7 months, median overall survival ("OS") increased from 16.33 to 28.94 months Clinical efficacy correlated with the magnitude of T cell responses specific to mutant-KRAS... ► Artikel lesen | |
| 12.08.25 | Elicio Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.08.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates | 331 | GlobeNewswire (Europe) | Recent positive recommendation by the Independent Data Monitoring Committee ("IDMC") to continue ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis Event-driven... ► Artikel lesen | |
| 16.04.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires | 321 | GlobeNewswire (Europe) | BOSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio Therapeutics" or "Elicio"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies... ► Artikel lesen | |
| 31.03.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates | 426 | GlobeNewswire (Europe) | Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival ("DFS") event-driven interim analysis expected in Q3 2025 Aligned with U.S. Food and Drug Administration ("FDA")... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,535 | +2,68 % | NanoRepro ordnet Aufsichtsrat nach außerordentlicher HV neu | Die Aktionäre der NanoRepro AG haben auf der außerordentlichen Hauptversammlung vom 16. Januar 2026 den Aufsichtsrat neu zusammengesetzt. Neu gewählt wurden Gunter Heneis, Michael Herrmann und Konstantin... ► Artikel lesen | |
| OCUGEN | 1,150 | +1,05 % | Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinical... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,745 | -1,29 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity | Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed
VK2735 Currently Being Evaluated in... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,550 | -5,49 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| BIOCRYST PHARMACEUTICALS | 5,392 | 0,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 | ||
| IBIO | 1,740 | -14,71 % | iBio, Inc.: iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update | Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented... ► Artikel lesen | |
| VAXART | 0,380 | 0,00 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,150 | -3,37 % | Arbutus Biopharma Corp - 8-K, Current Report | ||
| REDHILL BIOPHARMA | 1,070 | +7,00 % | RedHill Biopharma Ltd.: RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells | Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,352 | -0,44 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC | - Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in... ► Artikel lesen | |
| MANNKIND | 4,812 | -1,68 % | MannKind Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy | Updated initial conversion table based on clinical trials in adults showing significantly improved mealtime glycemic excursions DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| ALDEYRA | 4,700 | +0,38 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced... ► Artikel lesen | |
| TRAWS PHARMA | 1,960 | +13,95 % | Traws Pharma, Inc.: Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal ... | Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID- with fewer adverse events, no viral rebounds to date and faster time to sustained symptom resolution; results... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,747 | -3,29 % | Coherus Biosciences stock gains on JNJ clinical supply agreement |
ELICIO THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -9,93 % bei einem Aktienkurs von 6,350 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICIO THERAPEUTICS INC finden Sie auf Wallstreet Online.